Form 4: Cingulate Inc. SVP and CFO Jennifer L. Callahan Reports Stock Option Grant

Jennifer L. Callahan, SVP and CFO of Cingulate Inc., reports the acquisition of stock options.

Summary

• On February 18, 2025, Jennifer L. Callahan, SVP and CFO of Cingulate Inc., was granted stock options to purchase 21,140 shares of Cingulate Inc. common stock at an exercise price of $4.32.
• The options vest 25% on the one-year anniversary of the grant date and the remaining shares vest in substantially equal monthly installments over the following 36 months.
• Following the transaction, Ms. Callahan directly owns 21,140 derivative securities.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The grant of stock options is a standard practice and suggests confidence in the company's future performance.

Positives

• The grant of stock options to the CFO aligns her interests with those of the shareholders, incentivizing her to work towards increasing the company's value.

Industry Context

Stock option grants are a common form of executive compensation in the pharmaceutical industry, used to attract and retain talent and align management's interests with those of shareholders.

Stakeholder Impact

• The stock option grant could potentially benefit shareholders if the executive's performance leads to an increase in the company's stock price.

Key Dates

Keywords

stock options, Cingulate Inc., Form 4, insider trading, Jennifer L. Callahan, CFO, SVP, equity compensation, vesting